[Asia Economy Reporter Lee Chun-hee] Chong Kun Dang recently announced on the 3rd that it has launched 'Cantabel A,' a triple combination drug for hypertension and dyslipidemia.
Cantabel A is a product combining candesartan from the angiotensin II receptor blocker (ARB) class, amlodipine from the calcium channel blocker (CCB) class for hypertension treatment, and atorvastatin for dyslipidemia treatment. Cantabel A is the first triple combination drug of these ingredients in Korea.
Chong Kun Dang demonstrated the efficacy of Cantabel A for treating dyslipidemia and hypertension through a Phase 3 clinical trial conducted from 2018 to 2019 at 17 institutions in Korea. A total of 154 patients with hypertension accompanied by dyslipidemia were divided into three groups: Cantabel A administration group, candesartan + amlodipine combination group, and candesartan + atorvastatin co-administration group. After 8 weeks of drug administration, the Cantabel A group showed a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) levels compared to the control groups, and an improvement in mean systolic blood pressure (MSSBP) changes was also observed.
Chong Kun Dang launched Cantabel A in five different dosages?candesartan/amlodipine/atorvastatin at 8/5/10 mg, 8/5/20 mg, 16/5/10 mg, 16/5/20 mg, and 16/10/40 mg?allowing tailored prescriptions according to patient symptoms while also addressing the inconvenience of dose adjustment in fixed-dose combination (FDC) drugs.
A representative from Chong Kun Dang stated, "Cantabel A is the first triple combination drug introduced in Korea, providing a new treatment option for patients with hypertension accompanied by dyslipidemia. The domestic market lacks combination drugs based on atorvastatin, so we expect this to improve medication adherence among hypertensive patients taking this drug."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
